Explore TC BioPharm's recent Form 6-K filing detailing the ADS ratio change, trading impacts, and warrant adjustments, essential for investors and stakeholders.
Explore TC Biopharm's Form 6-K detailing a special dividend of 0.25 ADSs and warrant adjustments for January 2025.
Explore TC Biopharm's compliance challenges with Nasdaq, including its response to a delisting notification and plans for a hearing to maintain its market listing.
Discover TC Biopharm (Holdings) PLC's special dividend announcement, shareholder approval, and trading updates in this concise 6-K financial report overview.
TC BioPharm's December 2024 meeting highlights key resolutions on bonus shares and equity financing, showcasing strong shareholder support and strategic growth plans.